Local Bounti Q2 Top-Line Beats Street View
Local Bounti Corp (NYSE:LOCL) reported second-quarter FY22 sales of $6.27 million, beating the consensus of $5.25 million. The company reported $0.108…
MediPharm Labs Q2 Revenue Declines 14% YoY, Here Are The Details
MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) Q2 2022 revenue declined 14%, to CA$4.36 million ($3,37 million), compared to revenue of CA$5.07 million in Q2 2021.
This Analyst Boosts Price Target On Dillard’s; Also Check Out Some Other Big PT Changes
JP Morgan raised the price target for Dillard's, Inc. (NYSE: DDS) from $210 to $298. Dillard's shares rose 0.9% to $304.42 in pre-market trading.
Agrify Q2 Revenue Grows 63.5% YoY, What About Net Loss?
Agrify Corporation (NASDAQ: AGFY) released financial results for the second quarter ended June 30, 2022, revealing revenue of $19.3 million, an increase of 63.5% compared to $11.8 million for the prior year
This Analyst Raises PT On Karuna Therapeutics By 100%; Wells Fargo Predicts $2,300 For This Stock
Piper Sandler boosted the price target on First Solar, Inc. (NASDAQ: FSLR) from $120 to $165. Piper Sandler analyst Kashy Harrison maintained an Overweight rating on the stock. First Solar shares rose 0.7% to $118.83 in pre-market trading.
MDNA: Unconfirmed Partial Response in Pancreatic Cancer Patient…
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT
SAS Secures $700M In Debtor-In-Possession Financing
SAS AB (OTC:SASDY) has entered into a debtor-in-possession (DIP) financing credit agreement for $700 million with Apollo Global Management, Inc. (NYSE:APO). DIP financing…
S&P 500, Nasdaq Futures Slip From Multi-Month Highs: As China’s Economy Sneezes, Will Wall Street Catch A Cold?
The U.S. index futures are seen pulling back on Monday following buoyant performances in the week ended Aug. 12.
Why Is Turquoise Hill Resources Down By 18%: Here Are 31 Stocks Moving Premarket
Gainers
Plus Therapeutics, Inc. (NASDAQ: PSTV) shares rose 31.2% to $0.6931 in pre-market trading as the company presented positive data from ongoing ReSPECT™ clinical trials at the Annual Conference on CNS Clinical Trials and Brain Metastases.